Related Experiment Videos
FIV: from lentivirus to lentivector
Dyana T Saenz1, Eric M Poeschla
1Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
The Journal of Gene Medicine
|February 24, 2004
Summary
Researchers are improving feline immunodeficiency virus (FIV) vectors for gene therapy. This work enhances understanding of lentiviral vector development and permanent transgene integration in non-dividing cells.
Area of Science:
- Molecular virology
- Gene therapy vector development
- Lentivirus research
Background:
- Feline immunodeficiency virus (FIV) is a non-primate lentivirus.
- Understanding FIV's life cycle aids in developing improved gene therapy vectors.
- Key viral components like the packaging signal and DNA flap are being studied.
Purpose of the Study:
- To review advancements in FIV-based lentiviral vector development.
- To discuss the molecular basis of transgene integration in non-dividing cells.
- To highlight recent controversies and applications in preclinical models.
Main Methods:
- Mapping of the FIV packaging signal.
- Identification of a central DNA flap.
- Validation of class I integrase mutants.
Main Results:
- Development of FIV-derived lentiviral vectors with enhanced safety and efficacy.
- Demonstrated efficacy of these vectors in human tissues within preclinical models.
- Insights into the mechanism of permanent transgene integration in non-dividing cells.
Conclusions:
- FIV-based lentiviral vectors show promise for gene therapy applications.
- Continued research into FIV virology may unlock new therapeutic strategies.
- Understanding lentiviral integration is crucial for both pathogenesis and therapy.